Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin

被引：34

作者：

Steele, J. M. ^{[1
,2
]}

Seabury, R. W. ^{[1
]}

Hale, C. M. ^{[3
]}

Mogle, B. T. ^{[1
]}

机构：

[1] SUNY Upstate Med Univ, Dept Pharm, Univ Hosp, Syracuse, NY 13210 USA

[2] SUNY Upstate Med Univ, Dept Med, Syracuse, NY 13210 USA

[3] Penn State Milton S Hershey Med Ctr, Dept Pharm, Hershey, PA USA

来源：

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | 2018年 / 43卷 / 01期

关键词：

bacteremia; dalbavancin; endocarditis; MRSA; pregnancy; Staphylococcus aureus; DAPTOMYCIN; VANCOMYCIN; MECHANISMS; THERAPY; MODEL;

D O I：

10.1111/jcpt.12580

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

What is known and objectiveLimited evidence describes dalbavancin use in infective endocarditis (IE). Case descriptionA 27-year-old pregnant female received 4weeks of dalbavancin for methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia and tricuspid valve IE after conventional therapy was no longer an option due to non-compliance. Despite having a smaller cardiac vegetation following dalbavancin, she was bacteraemic <2weeks later with vancomycin-intermediate (VISA) and telavancin-non-susceptible S.aureus. What is new and conclusionThis is the first report of unsuccessful IE treatment with dalbavancin. Blood cultures grew VISA and lipoglycopeptide-non-susceptible S.aureus <2weeks following dalbavancin. Both outcomes raise concerns about using dalbavancin for IE.

引用

页码：101 / 103

页数：3

共 13 条

[1] Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review [J].

Al-Omari, Awad ;

Cameron, D. William ;

Lee, Craig ;

Corrales-Medina, Vicente F. .

BMC INFECTIOUS DISEASES, 2014, 14

[2]

[Anonymous], 2016, DALB PACK INS

[3] Physiologic and pharmacokinetic changes in pregnancy [J].

Costantine, Maged M. .

FRONTIERS IN PHARMACOLOGY, 2014, 5

[4] Right-side endocarditis in injection drug users: Review of proposed mechanisms of pathogenesis [J].

Frontera, JA ;

Gradon, JD .

CLINICAL INFECTIOUS DISEASES, 2000, 30 (02) :374-379

[5] Mechanisms of vancomycin resistance in Staphylococcus aureus [J].

Gardete, Susana ;

Tomasz, Alexander .

JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (07) :2836-2840

[6] Bactericidal activity and resistance development profiling of dalbavancin [J].

Goldstein, Beth P. ;

Draghi, Deborah C. ;

Sheehan, Daniel J. ;

Hogan, Patricia ;

Sahm, Daniel F. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (04) :1150-1154

[7] A Current Perspective on Daptomycin for the Clinical Microbiologist [J].

Humphries, Romney M. ;

Pollett, Simon ;

Sakoulas, George .

CLINICAL MICROBIOLOGY REVIEWS, 2013, 26 (04) :759-780

[8] Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model [J].

Jabés, D ;

Candiani, G ;

Romanó, G ;

Brunati, C ;

Riva, S ;

Cavaleri, M .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) :1118-1123

[9] Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin [J].

Lefort, A ;

Pavie, J ;

Garry, L ;

Chau, F ;

Fantin, B .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (03) :1061-1064

[10] Addition of Ceftaroline to Daptomycin after Emergence of Daptomycin-Nonsusceptible Staphylococcus aureus during Therapy Improves Antibacterial Activity [J].

Rose, Warren E. ;

Schulz, Lucas T. ;

Andes, David ;

Striker, Rob ;

Berti, Andrew D. ;

Hutson, Paul R. ;

Shukla, Sanjay K. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (10) :5296-5302

← 1 2 →